Novartis Reports Tumor Cases Linked to Zolgensma Gene Therapy
Novartis has identified nine reports of tumors in patients treated with its gene therapy Zolgensma since its 2019 approval, with two cases showing evidence of a link to the treatment.
Stocks · News reference
Novartis Italia Presents Catalyst Project
Novartis Italia introduced its Catalyst project during the 'Innovazione che cambia la vita' event, highlighting new initiatives in the local market.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Schrödinger Amends Collaboration Agreement with Novartis
Schrödinger has amended its existing collaboration with Novartis, replacing previous programs with two new ones and increasing potential milestone payments to $1.424 billion.
Novartis Venture Fund Participates in €40 Million Series A Financing for Anaheim Bio
Novartis Venture Fund joined a group of investors in a €40 million Series A financing round for the newly launched Dutch biotechnology company Anaheim Bio.
Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
Monte Rosa Therapeutics announced positive Phase 1 results for MRT-8102, showing significant NEK7 degradation and reduction in cardiovascular disease markers with safety comparable to placebo. The company plans to initiate three Phase 2 studies in gout, coronary artery disease, and hidradenitis suppurativa. Additionally, Novartis initiated Phase 2 studies of partnered program MRT-6160 in Sjögren's disease and psoriatic arthritis, triggering $87.5 million in milestone payments. The company maintains a strong cash position of $582.6 million, expected to support operations into 2029.
Novartis: 3 Key Takeaways for Long-Term Investors
Novartis raised its full-year 2026 core operating income guidance to in-line to low-single-digit growth after delivering 4% net sales growth in Q3 2026. The company is successfully offsetting patent expirations through sales of newly launched priority medicines, with Rhapsido peak sales guidance upgraded to over $4 billion. Operating margins are on track to reach 40% by 2029 as SG&A expenses fell 7% while maintaining top-line growth.
Novartis Updates Phase IV STREAM Study for SMA Treatment
Novartis has expanded recruitment sites for its Phase IV STREAM study evaluating the safety and effectiveness of onasemnogene abeparvovec in patients with spinal muscular atrophy.